Management of B-ALL in the Era of Targeted Immunotherapy
- Review the clinical significance of long term survival data of the novel therapies in relapsed/refractory B-ALL
- Understand optimal sequencing and how treatment decisions are made given the patient profile
- Discuss the different approaches and strategies in managing and mitigating the risks of AEs
Registration is complimentary and restricted to healthcare professionals. Please click the button below to complete the transaction:
About the Faculty
Dr. Dina Khalaf
Dr. Dina Khalaf, MD, MSC, is a Hematologist at the JuravinskiCancer Centre.She holds a faculty staff position as an Assistant Professor in the Department of Medicine at McMaster University.Dina completed an Internal Medicine fellowship at University Health Network, Toronto, followed by a Malignant Hematology Fellowship at Princess Margaret Hospital. Her practice focuses on myeloid malignancies, and she has a special interest in clinical education.
Dr. Partow Kebriaei
Dr. Kebriaei received her BS degree from Yale University in 1993, and her MD degree from the University of Texas at Houston medical school in 1997. She went on to receive her Internal Medicine training at University of Texas Southwestern in Dallas, and completed a fellowship in Hematology and Oncology at the University of Chicago in 2000.
She joined the stem cell transplant department at MD Anderson Cancer Center (MDACC) in 2003.
Dr. Kebriaei’s research interests include therapy of leukemias, in particular acute lymphoblastic leukemia, as well as autologous and allogeneic stem cell transplantation for lymphoma and leukemia. She is interested in the development of novel transplant preparative regimens that may have less regimen-related toxicity, and increased disease efficacy. More specifically, she is interested in investigating the use of traditional chemotherapeutic agents in combination with cellular therapies and adoptive immunotherapy to develop more effective treatment regimens. Work toward this aim
includes investigating the use CD19-directed T cell therapy for lymphoid malignancies, using umbilical cord blood in combination with a standard allogeneic peripheral blood stem cell transplant to augment the graft versus leukemia effect, and investigating the use of mesenchymal stem cells for the therapy of graft versus host disease.
Dr. Kebriaei is the principal investigator of 10 currently active phase I/II clinical trials at MDACC, has authored numerous reviews, book chapters, and papers, and serves as a reviewer for major hematology and oncology publications. She is an active member of hematology and oncology professional societies including American Association for Cancer Research, American Society of Hematology, American Society of Clinical Oncology, and American Society for Blood and Marrow Transplantation.
This program has been made possible through unrestricted support from Pfizer.